Fig 2.

Prevention of the norepinephrine-induced increases in PLC isozyme protein content and activity in siRNA transfection of cardiomyocytes. Representative blots (A) showing PLC isozyme β₁ (150 kD), β₃ (150 kD), γ₁ (145 kD) and δ₁ (87 kD) protein levels in cardiomyocytes. Quantified data shows PLC β₁ (B), β₃ (C), δ₁ (D) and γ₁ (E) protein content in cardiomyocytes transfected with 5 nM PLC β₁, β₃, γ₁ and δ₁ siRNA and treated with NE (5 μM) for 24 hrs. The PLC isozyme activities (F) were determined in siRNA transfected cardiomyocytes following immunoprecipitation and hydrolysis of ³[H]-PIP₂. preparations. Control cardiomyocytes were transfected with 5 nM negative control siRNA as described in ‘materials and methods’ section. Values are mean ± S.E. of five experiments performed with five different cardiomyocyte preparations. *Significantly different (P < 0.05) versus control; ^#significantly different (P < 0.05) versus. NE. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; CONT, control; NC, negative control; NE, norepinephrine; siRNA, small interfering RNA.